A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies
Latest Information Update: 30 Sep 2024
At a glance
- Drugs MGD 024 (Primary)
- Indications Acute myeloid leukaemia; Blastic plasmacytoid dendritic cell neoplasm; Chronic myeloid leukaemia; Hairy cell leukaemia; Hodgkin's disease; Mastocytosis; Myelodysplastic syndromes; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; First in man
- Sponsors MacroGenics
- 23 Sep 2024 Planned number of patients changed from 90 to 130.
- 23 Sep 2024 Planned End Date changed from 1 Mar 2025 to 1 Oct 2025.
- 23 Sep 2024 Planned primary completion date changed from 1 Mar 2025 to 1 Oct 2025.